Eupraxia Pharmaceuticals (NASDAQ:EPRX) Upgraded at Wall Street Zen

Key Points

• Wall Street Zen upgraded Eupraxia Pharmaceuticals from “strong sell” to “sell,” while broader analyst coverage remains more positive, with a “Moderate Buy” consensus and an average price target of $18.00.
• EPRX shares rose 5.0% to open at $8.42, compared with a 52-week range of $5.16 to $9.32. The company also reported a quarterly loss of $0.23 per share, beating estimates by $0.02.
• Several institutional investors increased their holdings, including JPMorgan Chase, Bank of America, UBS, and Raymond James, while Eupraxia continues developing therapies for autoimmune and inflammatory diseases.

Eupraxia Pharmaceuticals (NASDAQ:EPRX - Get Free Report) was upgraded by investment analysts at Wall Street Zen from a "strong sell" rating to a "sell" rating in a report issued on Saturday, Wall Street Zen reports.

A number of other brokerages have also weighed in on EPRX. Cantor Fitzgerald restated an "overweight" rating on shares of Eupraxia Pharmaceuticals in a research note on Wednesday, July 15th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Eupraxia Pharmaceuticals in a research report on Friday, July 17th. Stifel Nicolaus began coverage on shares of Eupraxia Pharmaceuticals in a research note on Thursday, May 21st. They issued a "buy" rating and a $25.00 target price for the company. Finally, Oppenheimer started coverage on shares of Eupraxia Pharmaceuticals in a research report on Thursday, June 25th. They set an "outperform" rating and a $17.00 target price on the stock. Two analysts have rated the stock with a Strong Buy rating, five have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $18.00.

Eupraxia Pharmaceuticals Stock Up 5.0%

Shares of EPRX stock opened at $8.42 on Friday. Eupraxia Pharmaceuticals has a 1-year low of $5.16 and a 1-year high of $9.32. The stock's fifty day moving average price is $6.84 and its 200 day moving average price is $6.99. The company has a debt-to-equity ratio of 0.02, a current ratio of 16.00 and a quick ratio of 16.00. The company has a market cap of $547.46 million, a price-to-earnings ratio of -8.25 and a beta of 1.07.

Eupraxia Pharmaceuticals (NASDAQ:EPRX - Get Free Report) last announced its earnings results on Tuesday, August 11th. The company reported ($0.23) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.25) by $0.02. On average, research analysts expect that Eupraxia Pharmaceuticals will post -0.85 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the company. Royal Bank of Canada lifted its holdings in shares of Eupraxia Pharmaceuticals by 21.1% during the first quarter. Royal Bank of Canada now owns 342,828 shares of the company's stock worth $1,125,000 after purchasing an additional 59,683 shares during the period. JPMorgan Chase & Co. increased its holdings in Eupraxia Pharmaceuticals by 593.2% in the 2nd quarter. JPMorgan Chase & Co. now owns 18,717 shares of the company's stock worth $108,000 after buying an additional 16,017 shares during the period. Bank of America Corp DE increased its holdings in Eupraxia Pharmaceuticals by 402.4% in the 2nd quarter. Bank of America Corp DE now owns 12,559 shares of the company's stock worth $72,000 after buying an additional 10,059 shares during the period. UBS Group AG raised its position in Eupraxia Pharmaceuticals by 155.4% during the 3rd quarter. UBS Group AG now owns 95,756 shares of the company's stock worth $565,000 after buying an additional 58,257 shares during the last quarter. Finally, Raymond James Financial Inc. raised its position in Eupraxia Pharmaceuticals by 173.3% during the 3rd quarter. Raymond James Financial Inc. now owns 33,373 shares of the company's stock worth $197,000 after buying an additional 21,161 shares during the last quarter.

Eupraxia Pharmaceuticals Company Profile

Eupraxia Pharmaceuticals, Inc NASDAQ: EPRX is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for autoimmune and inflammatory diseases. The company's core strategy centers on selectively expanding regulatory T cells (Tregs)—immune cells responsible for maintaining self-tolerance and limiting pathological inflammation—through its proprietary platform. Its lead therapeutic candidate is currently in Phase 1 clinical development in patients with systemic lupus erythematosus.

Based in Seattle, Washington, Eupraxia Pharmaceuticals conducts research and development activities across North America, collaborating with academic institutions and contract research organizations to advance its pipeline.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.